Clinical Trial Update: Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Ombitasvir/Paritaprevir/Ritonavir for genotype 1b chronic hepatitis C virus infection in Japanese adults with end-stage renal disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Technivie (Ombitasvir/paritaprevir/ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Virus | Phase 3 | Status: WITHDRAWN